Recruiting studies: Refractory Anemia With Excess Blasts

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360 BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 · 1 location(s) · Eric Stephen Winer, MD · NCT05703542 Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297576 Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077 Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increa
Phase 1 · 5 location(s) · National Cancer Institute (NCI) · NCT03816319 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034 A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171 Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 · 2 location(s) · Istituto Clinico Humanitas · NCT06892223 HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase 2 · 3 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02143830 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424 Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Phase 2 · 1 location(s) · Kirsten Grønbæk · NCT04741945 Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
Phase 2 · 1 location(s) · Hannah Choe, MD · NCT07249346 WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory St
Phase N/A · 1 location(s) · University of Oxford · NCT07511829 Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Phase 1/Phase 2 · 3 location(s) · ARCE Therapeutics, Inc. · NCT06680752 Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489 Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT01861106 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966 Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187 Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06303193 MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717 Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character o
NA · 1 location(s) · University Hospital, Bordeaux · NCT04800458 A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Phase 1 · 9 location(s) · Apollo Therapeutics Ltd · NCT06372717 Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Us
Phase 2 · 2 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT01174108 Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Phase N/A · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06111612 Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Phase 1/Phase 2 · 2 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT07532824

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.